Alteogen has won Korean approval for Eyzanfy, its biosimilar version of Regeneron and Bayer’s retinal disease drug Eylea (aflibercept), adding another lower-cost competitor to Korea’s ophthalmology market

Eyluxvi (aflibercept biosimilar) - Alteogen, Biolitec, Hanlim Pharma

May 15, 2026